You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

329 Results
Document
Jan 2023
Document
Jan 2023
Guidelines and Advice
Status: Current
ID: PET 2022-1
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
Document
Jan 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
fluorouracil,
EPIrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Guidelines and Advice
Status: Current
Version: 1
Apr 2023
Document
Apr 2023
Document
Apr 2023
Drug
Other Name(s): Braftovi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Apr 2024

Pages